Celyad Announces Successful Dosing of CYAD-01 IV in P-I THINK Trial for the Treatment of mCRC

 Celyad Announces Successful Dosing of CYAD-01 IV in P-I THINK Trial for the Treatment of mCRC

Celyad Announces Successful Dosing of CYAD-01 IV in P-I THINK Trial for the Treatment of mCRC

Shots:
  • The P-I THINK ongoing trial is assessing CYAD-01 in mCRC patients administering cyclophosphamide (300 mg/m²) and fludarabine (30 mg/m²), evaluating its safety and ATR
  • CYAD-01 investigational CAR-T therapy with expressing NKG2D receptor of NK cells, administration has shown no toxicity till date in its first enrolled patient in THINK trial  
  • CYAD-01 is under clinical stage with number of trials for haematological malignancies and solid tumours
Click here to read full press release/ article | Ref: Celyad | Image:  PRNewswire

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post